ImmuCell Corp (ICCC) 8-K Summary
Business Context and Reporting Period
This Form 8-K Current Report was filed by ImmuCell Corporation on February 9, 2026. The company is incorporated in Delaware and its common stock trades on The Nasdaq Capital Market under the symbol ICCC. The report addresses corporate governance changes regarding the Board of Directors.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on non-financial corporate events.
Material Changes
Two directors, Steven A. Rosgen and Bryan K. Gathagan, have notified the company that they will not seek re-election at the 2026 Annual Meeting of Shareholders. Both directors cited time constraints due to full-time leadership roles at their respective companies as the reason for their departure. The company notes that both directors have been supportive of the company's new strategic direction and management team.
Outlook and Management Commentary
The Nominating Committee is currently evaluating changes to the Board composition and will incorporate these upcoming retirements into its ongoing work. No specific financial guidance, risks, or contingencies were disclosed in this filing.
Key Facts for Investors
- Two directors (Steven A. Rosgen and Bryan K. Gathagan) are stepping down and will not run for re-election.
- The departures are attributed to time constraints from other full-time leadership roles, not strategic disagreements.
- The Nominating Committee is actively working to evaluate potential new board members.
- No financial performance data or material financial risks were disclosed in this specific report.